GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PMV Pharmaceuticals PMVP · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.88

-33.13%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

PMV Pharmaceuticals — daily PMVP Delayed
Market value
$46.0m
Last close × shares
Volume
4.8m
Shares, 20 Nov 2026

About PMV Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

PMV Pharmaceuticals is based in Princeton, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PMVP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $77.7m. At that date it held total assets of $116.6m and shareholders' equity of $104.7m.

In its own words

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target p53 mutations and other p53-related cancers.

Our lead product candidate, rezatapopt, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. The p53 Y220C mutation is associated with approximately 1% of all cancers, including endometrial, breast, non-small cell lung cancer, or NSCLC, colorectal, pancreatic and notably, approximately 3% of ovarian cancers.

Quoted from its 10-K, filed 6 Mar 2026. Read the filing on SEC.gov ↗

More about PMV Pharmaceuticals →

Latest on PMV Pharmaceuticals

Our reporting

Next results

5 Mar 2027

Due on 5 Mar 2027. Analysts expect earnings of -0.27 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is PMV Pharmaceuticals's ticker?

PMV Pharmaceuticals trades as PMVP on its US listing, under ISIN US69353Y1038.

What was PMV Pharmaceuticals's last closing price?

0.88 on 20 Nov 2026. The figure is in USD and is never converted.

When does PMV Pharmaceuticals next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.